TY - JOUR T1 - Understanding the value of clinical symptoms of COVID-19. A logistic regression model JF - medRxiv DO - 10.1101/2020.10.07.20207019 SP - 2020.10.07.20207019 AU - Pedro E. Fleitas AU - Jorge A. Paz AU - Mario I. Simoy AU - Carlos Vargas AU - Rubén O. Cimino AU - Alejandro J. Krolewiecki AU - Juan P. Aparicio Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/16/2020.10.07.20207019.abstract N2 - Background The new coronavirus SARS-CoV-2, the causative agent of COVID-19, is responsible for the current pandemic outbreak worldwide. However, there is limited information regarding the set of specific symptoms of COVID-19. Therefore, the objective of this study was to describe the main symptoms associated with COVID-19 to aid in the clinical diagnosis for the rapid identification of cases.Methods and findings A cross sectional study of all those diagnosed by RT-PCR for SARS-CoV-2 between April 1 and May 24 in Argentina was conducted. The data includes clinical and demographic information from all subjects at the time of presentation, which were uploaded to the centralized national reporting system at health centers. A total of 67318 individuals were included in this study, where 12% tested positive for SARS-CoV-2. The study population was divided in two age groups, a group aged 0 to 55 years-old (<56 group), (median = 32, n=48748) and another group aged 56 to 103 years-old (≥56 group) (median =72, n=18570). Multivariate logistic regression analyses showed that out of a total of 23 symptoms, only five were found to have a positive association with COVID-19: anosmia (odds ratio [OR] 10.40, 95% confidence interval [CI] 8.20-13.10, <56 group; OR 6.09 CI 3.05-12.20, ≥56 group) dysgeusia (OR 3.67, CI 2.7-4.9, <56 group; OR 3.53 CI 1.52-8.18, ≥56 group), low grade fever (37.5-37.9° C) (OR 1.61, CI 1.20-2.05, <56 group; OR 1.80 CI 1.07-3.06, ≥56 group), cough (OR 1.20, CI 1.05-1.38, <56 group; OR 1.37 CI 1.04-1.80, ≥56 group) and headache only in <56 group (OR 1.71, CI 1.48-1.99). In turn, at the time of presentation, the symptoms associated with respiratory problems: chest pain, tachypnea, dyspnea, respiratory failure and use of accessory muscles for breathing, had a negative association with COVID-19 (OR <1) or did not present statistical relevance (OR = 1).With the intention of helping the clinical diagnosis, we designed a model to be able to identify possible cases of COVID-19. This model included 16 symptoms, the age and sex of the individuals, and was able to detect 80% of those infected with SARS-CoV-2 with a specificity of 46%.Conclusions The analysis of symptoms opens the opportunity for a guidance and improved symptoms based definition of suspected cases of COVID-19, where multiple factors (age, sex, symptoms and interaction between symptoms) are considered. We present a tool to help identify COVID-19 cases to provide quick information to aid decision-making by health personnel and program managers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data are openly available to the public through the website of the Argentine Ministry of Health. In addition, according to Law 25,326 Article 5 of Argentina, consent or ethical approval is not necessary when the data comes from sources of unrestricted public access. Link of the Law https://www.argentina.gob.ar/normativa/nacional/ley-25326-64790/actualizacionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data files is available from the website of National Ministry of Health of Argentina http://datos.salud.gob.ar/dataset/covid-19-determinaciones-registradas-en-la-republica-argentina ER -